This product is available for Research Use Only (RUO) outside the U.S. An in vitro diagnostic version of this product is available for use in Canada, Japan, Phillipines, Singapore, and U.S., under each country's respective authorizing agency.
COVIDSeq Test (RUO Version)
This high-throughput next-generation sequencing (NGS) assay detects mutations from the SARS-CoV-2 virus.
Key Features and Benefits
Accurate: Detects 98 targets on SARS-CoV-2 RNA for highly accurate detection of mutations
Comprehensive: Reports consensus sequence for virus genome analysis
Quality Controlled: Built-in quality control features in every reaction
Flexible: Seamless end-to-end workflow. Temperature specification allows use of different thermocyclers
Scalable: Available on NovaSeq 6000, NextSeq 2000, or NextSeq 500/550/550Dx (in RUO mode) systems
The Illumina COVIDSeq Test (RUO version), an amplicon-based NGS assay, includes 2019-nCoV primers designed to detect mutations and characterize RNA from the SARS-CoV-2 virus to help clinical research labs identify and track the emergence and prevalence of novel strains of SARS-CoV-2.
Rapid, Scalable SARS-CoV-2 Detection
The Illumina COVIDSeq Test (RUO version) can be scaled up or down to accommodate different numbers of samples. 1536 to 3072 results can be processed in 12 hours on NovaSeq 6000 system using two SP or S4 reagent kits, respectively or 384 results in 12 hours using NextSeq 2000 P2 v3 reagent kits or NextSeq 500/550/550Dx (in Research Mode) HO reagent kit.
Workflow and Components
The workflow includes steps for viral RNA extraction, RNA-to-cDNA conversion, PCR, library preparation, sequencing, analysis, and report generation. Key components include the high-throughput NovaSeq 6000 System or the NextSeq 2000 System or the NextSeq 500/550/550Dx (in Research Mode) Systems, coupled with the Illumina COVIDSeq Test (RUO version) and the DRAGEN COVIDSeq Test App (RUO version) in BaseSpace Sequence Hub for rapid analysis.
Design and Quality Control
The Illumina COVIDSeq Test (RUO version) leverages a modified version of the validated, publicly available ARTIC multiplex PCR protocol, with 98 amplicons designed to amplify SARS-CoV-2 virus-specific sequences, combined with proven Illumina sequencing technology. COVIDSeq provides consensus sequence information when +90 amplicons are detected. A 63°C annealing temperature at the PCR step improves variant analysis—providing important insight into the SARS-CoV-2 strain present in the sample, and enabling tracking of virus strains.
The COVIDSeq V4 Primer Pool is available as an RUO product. It is based on ARTIC network V4 design and includes 99 amplicons and no human controls. The kit volume is sufficient for 384 samples. This product is not available in all countries/regions. Please contact your local sales representative for availability.
Consensus sequence information (FASTA file) can be uploaded into open software tools to assign lineage and annotate mutations. FASTA files can be easily uploaded to the NCBI and/or GISAID App directly through BaseSpace Sequencing Hub for added convenience.